Histopathological response of transitional cell carcinoma to arsenic trioxide during the treatment of concurrently diagnosed acute promyelocytic leukaemia.
Krishna
R
R
Sorour
Y
Y
Goepel
J R
JR
Kirkbride
P
P
Smith
D J
DJ
Ezaydi
Y
Y
Dalley
C D
CD
Snowden
J A
JA
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000473:pathology*; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy* / Q000473:pathology*; D010087:Oxides / Q000008:administration & dosage*; D012074:Remission Induction; D014212:Tretinoin / Q000008:administration & dosage*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology*
D001152:Arsenicals; D010087:Oxides; D014212:Tretinoin; D000077237:Arsenic Trioxide